Eloxx Pharmaceut Financials
This page shows Eloxx Pharmaceut (ELOX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 27 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is carrying a cash-burning business whose remaining obligations sit in short-term liabilities rather than debt.
The key improvement in FY2025 is that cash was rebuilt by financing, not operations: financing cash flow of$11.0M more than offset operating cash use of-$6.3M , so the higher cash balance does not reflect self-funding. Even with that refill, the working-capital position only improved from 0.1x to 0.3x, meaning near-term obligations still outweigh near-term resources by a wide margin.
Balance-sheet strain eased, with total liabilities falling from
The expense base has been dramatically resized: SG&A fell from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Eloxx Pharmaceut's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Eloxx Pharmaceut carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.
Eloxx Pharmaceut's current ratio of 0.31 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Eloxx Pharmaceut passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Eloxx Pharmaceut generates $1.06 in operating cash flow (-$6.3M OCF vs -$6.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Eloxx Pharmaceut generated $0 in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Eloxx Pharmaceut's EBITDA was -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 164.6% from the prior year.
Eloxx Pharmaceut reported -$6.0M in net income in fiscal year 2025. This represents a decrease of 90.7% from the prior year.
Eloxx Pharmaceut earned $-0.49 per diluted share (EPS) in fiscal year 2025. This represents an increase of 41.7% from the prior year.
Cash & Balance Sheet
Eloxx Pharmaceut held $4.8M in cash against $0 in long-term debt as of fiscal year 2025.
Eloxx Pharmaceut had 5M shares outstanding in fiscal year 2025. This represents an increase of 35.5% from the prior year.
Margins & Returns
Capital Allocation
Eloxx Pharmaceut invested $3.1M in research and development in fiscal year 2025. This represents a decrease of 14.6% from the prior year.
ELOX Income Statement
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.7M | N/A | $510K | N/A | N/A | $1.3M-46.5% | $2.3M-33.0% | $3.5M |
| SG&A Expenses | $2.1M | N/A | $712K | N/A | N/A | $2.4M+32.5% | $1.8M-9.7% | $2.0M |
| Operating Income | -$3.8M | N/A | -$1.2M | N/A | N/A | -$3.6M+12.1% | -$4.1M+24.5% | -$5.5M |
| Interest Expense | $100K | N/A | $500K | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.8M | N/A | -$1.7M | N/A | N/A | -$3.6M+17.3% | -$4.3M+30.3% | -$6.2M |
| EPS (Diluted) | $-0.08 | N/A | $-0.45 | N/A | N/A | $-1.31+33.2% | $-1.96+31.9% | $-2.88 |
ELOX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.5M+61.3% | $5.3M | N/A | $3.0M+73.8% | $1.7M-71.7% | $6.0M+0.8% | $6.0M-16.8% | $7.2M |
| Current Assets | $8.5M+61.3% | $5.3M | N/A | $3.0M+92.2% | $1.5M-72.5% | $5.6M+4.6% | $5.4M-15.9% | $6.4M |
| Cash & Equivalents | $6.4M+33.0% | $4.8M+963.3% | $450K+305.4% | $111K-90.2% | $1.1M-76.3% | $4.8M+10.3% | $4.3M-11.7% | $4.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $16.1M-6.3% | $17.2M | N/A | $27.3M+12.3% | $24.3M-6.8% | $26.1M+6.1% | $24.6M+370.4% | -$9.1M |
| Current Liabilities | $16.1M-6.3% | $17.2M | N/A | $27.3M+20.3% | $22.7M-3.3% | $23.5M+10.4% | $21.3M+9.2% | $19.5M |
| Long-Term Debt | N/A | $0 | N/A | $0-100.0% | $1.6M-38.5% | $2.6M-21.4% | $3.3M-17.2% | $4.0M |
| Total Equity | -$7.6M+36.3% | -$11.9M+54.2% | -$26.0M-6.9% | -$24.3M-7.7% | -$22.6M-12.7% | -$20.0M-7.8% | -$18.6M-214.1% | $16.3M |
| Retained Earnings | -$304.3M-1.2% | -$300.6M | N/A | -$294.6M-1.1% | -$291.4M-1.0% | -$288.6M-1.3% | -$285.0M-1.5% | -$280.6M |
ELOX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.5M | N/A | $1.2M | N/A | -$2.0M+41.7% | -$3.5M-67.0% | -$2.1M+69.7% | -$6.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$3.5M-67.0% | -$2.1M+69.7% | -$6.8M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | $51K-78.1% | $233K+1564.3% | $14K+27.3% | $11K |
| Financing Cash Flow | $7.0M | N/A | -$865K | N/A | -$1.7M-145.8% | $3.7M+157.0% | $1.4M+119.0% | -$7.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ELOX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q1'25 | Q4'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -38.2% |
| Return on Assets | -44.1% | N/A | N/A | N/A | N/A | -59.5%+13.0pp | -72.4%+14.1pp | -86.5% |
| Current Ratio | 0.53+0.2 | 0.31 | N/A | 0.11+0.0 | 0.07-0.2 | 0.24-0.0 | 0.25-0.1 | 0.33 |
| Debt-to-Equity | -2.12-2.1 | 0.00 | N/A | 0.00+0.1 | -0.07+0.1 | -0.13+0.0 | -0.18-0.4 | 0.25 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$11.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.31), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Eloxx Pharmaceut's annual revenue?
Eloxx Pharmaceut (ELOX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Eloxx Pharmaceut's revenue growing?
Eloxx Pharmaceut (ELOX) revenue declined by 100% year-over-year, from $6.4M to $0 in fiscal year 2025.
Is Eloxx Pharmaceut profitable?
No, Eloxx Pharmaceut (ELOX) reported a net income of -$6.0M in fiscal year 2025.
What is Eloxx Pharmaceut's EBITDA?
Eloxx Pharmaceut (ELOX) had EBITDA of -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Eloxx Pharmaceut have?
As of fiscal year 2025, Eloxx Pharmaceut (ELOX) had $4.8M in cash and equivalents against $0 in long-term debt.
What is Eloxx Pharmaceut's operating cash flow?
Eloxx Pharmaceut (ELOX) generated -$6.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Eloxx Pharmaceut's total assets?
Eloxx Pharmaceut (ELOX) had $5.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Eloxx Pharmaceut spend on research and development?
Eloxx Pharmaceut (ELOX) invested $3.1M in research and development during fiscal year 2025.
What is Eloxx Pharmaceut's current ratio?
Eloxx Pharmaceut (ELOX) had a current ratio of 0.31 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Eloxx Pharmaceut's debt-to-equity ratio?
Eloxx Pharmaceut (ELOX) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Eloxx Pharmaceut's return on assets (ROA)?
Eloxx Pharmaceut (ELOX) had a return on assets of -113.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Eloxx Pharmaceut's cash runway?
Based on fiscal year 2025 data, Eloxx Pharmaceut (ELOX) had $4.8M in cash against an annual operating cash burn of $6.3M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Eloxx Pharmaceut's debt-to-equity ratio negative or unusual?
Eloxx Pharmaceut (ELOX) has negative shareholder equity of -$11.9M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Eloxx Pharmaceut's Piotroski F-Score?
Eloxx Pharmaceut (ELOX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Eloxx Pharmaceut's earnings high quality?
Eloxx Pharmaceut (ELOX) has an earnings quality ratio of 1.06x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Eloxx Pharmaceut?
Eloxx Pharmaceut (ELOX) scores 15 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.